For all investor queries, please contact info@vasomune.com.
Latest News
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001
https://www.businesswire.com/news/home/20240528034965/en/Vasomune-Therapeutics-Receives-US-FDA-Fast-Track-Designation-for-Novel-Investigational-Medicine-AV-001
May 30, 2024
No Comments
American Thoracic Society Selects Vasomune Therapeutics Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
AV-001 is a first-in-class drug candidate designed to fight disease by boosting vascular endothelial stability TORONTO, April 15, 2024, 2024 (BUSINESS WIRE) – Vasomune Therapeutics
April 24, 2024
No Comments
AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
November 14, 2023
No Comments
Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease
Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. January 18, 2022 08:00 AM
January 18, 2022
No Comments